

# Myasthenia Gravis (MG) Australian Survey 2022

## A Summary for Participants

### Study objective: What did we hope to achieve?


Generate evidence required to advocate for people living with MG to have timely and equitable access to better health service, better funding, and more reimbursement pathways.

### Study design: How did we collect the data?

Surveyed MG patients electronically about quality of life, personal histories with MG, and the financial and clinical aspects of living with MG.

**280** Respondents **Average Age 60.5**

67.5% Female 32.1% Male 0.4% Nonbinary



Average **2.9** years from first symptoms to diagnosis


1.5 Years Male

3.6 Years Female


50% from capital cities | 50% from regional areas

### Participant Experience With MG

Most were limited in daily tasks and activities




During the past 12 months:



During the past 12 months:


**48%** required additional medical intervention

Those who required additional intervention reported out-of-pocket spending:




Participants reported their treatments used, currently or in the past

All current and previous medications and procedures\*



Current medications and procedures\*



**33.7%** reported that their thymus had been removed

Next steps: What will we do with this data?

- Share it with neurologists in clinical conference
- Publish it later in 2022
- Use it in dialogue with the Minister of Health as part of a larger effort to improve treatment options

\*These categories are not mutually exclusive.